Neurocrine Biosciences announced that Kevin Gorman, Ph.D., will retire as CEO of Neurocrine on October 11, 2024. Kyle Gano, Ph.D., currently Neurocrine’s Chief Business Development and Strategy Officer, will succeed him in the CEO role. Dr. Gano will also join the company’s Board of Directors at that time, and Dr. Gorman will continue to serve on the Neurocrine Board. Kyle Gano, Ph.D., is a proven executive who joined Neurocrine Biosciences more than 23 years ago.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- RBC still sees gradual uptake for Neurocrine after competitor data
- Neurocrine competitive data should be kept in perspective, says Evercore
- Neurocrine announces publication of data from Phase 3 KINECT-4 study of INGREZZA
- Neurocrine presents baseline data of CAH program
- Neurocrine initiated with an Outperform at Evercore ISI